We strive for a better understanding of the spectrum and the accumulation of gut-derived metabolites in CKD and their stage-specific renal clearance dynamics. We want to use this knowledge to therapeutically target microbiota in CKD in the future and to develop novel diagnostic tools to identify CKD patients at a particularly high risk of developing advanced CKD, as well as inflammatory and cardiovascular complications.
We will induce experimental CKD by using two established mouse models. Most importantly, mice with different colonization statuses will be used to elucidate the impact of the gut microbiota. Metabolite landscapes from faeces, blood, urine and interstitial fluid will be measured in different stages of CKD development. Human cohort data will be used to verify findings in CKD patients. Furthermore, dietary intervention in experimental CKD will be performed in order to beneficially modify the microbial function.
We expect to better define and understand the spectrum of gut-derived metabolites and their toxic accumulation in different body compartments in CKD. This knowledge could enable novel avenues for the prognostic evaluation and treatment of CKD and its inflammatory and cardiovascular complications.